| Literature DB >> 33492870 |
Jimmy Faivre1, Mélanie Gallet, Elodie Tremblais, Patrick Trévidic, François Bourdon.
Abstract
BACKGROUND: Crosslinked hyaluronic acid (HA)-based soft tissue fillers possess unique viscoelastic properties intended to match specific product indications. Manufacturing has an impact on HA chain integrity and on filler properties.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33492870 PMCID: PMC8078113 DOI: 10.1097/DSS.0000000000002916
Source DB: PubMed Journal: Dermatol Surg ISSN: 1076-0512 Impact factor: 2.914
Library of the Studied Dermal Fillers Classified According to Their Clinical Indications, Their Manufacturer, Their Process Technology, and Their Hyaluronic Acid Concentration
| Indication | Filler | Abbreviation | Manufacturer | Technology | HA Concentration (mg/mL) | Batch References | Needle Size |
| Fillers for superficial wrinkles | Restylane® SkinboostersTM Vital | RESSV | GALDERMA | NASHATM | 20 | 17633-1 | 29G × 1/2″ |
| Juvederm® VoliteTM | VYC-12L | ALLERGAN | Vycross® | 12 | V12LA90739 | 32G × 1/2″ | |
| Juvederm® VolbellaTM | VYC-15L | ALLERGAN | Vycross® | 15 | V15LA90261 | 30G × 1/2″ | |
| TEOSYAL RHA® 1 | RHA1 | TEOXANE | Preserved Network | 15 | TPRL-192512A | 30G × 1/2″ | |
| Fillers for mid-to-deep wrinkles | Restylane® Lido | RES | GALDERMA | NASHATM | 20 | 17604-1 | 29G × 1/2″ |
| Restylane® RefyneTM | RESREF | GALDERMA | OBTTM/XpresHAnTM Technology | 20 | 17523 | 30G × 1/2″ | |
| Restylane® DefyneTM | RESDEF | GALDERMA | OBTTM/XpresHAnTM Technology | 20 | 17360 | 27G × 1/2″ | |
| Juvederm® VoliftTM | VYC-17.5L | ALLERGAN | Vycross® | 17.5 | V17LA90320 | 30G × 1/2″ | |
| TEOSYAL RHA® 2 | RHA2 | TEOXANE | Preserved Network | 23 | TP30L-192321A | 30G × 1/2″ | |
| TEOSYAL RHA® 3 | RHA3 | TEOXANE | Preserved Network | 23 | TP27L-192312A | 27G × 1/2″ | |
| Volumizers | Restylane® LyftTM Lido | RESLYFT | GALDERMA | NASHATM | 20 | 17460-1 | 29G × 1/2″ |
| Juvederm® VolumaTM | VYC-20L | ALLERGAN | Vycross® | 20 | VB20A80852 | 27G × 1/2″ | |
| TEOSYAL RHA® 4 | RHA 4 | TEOXANE | Preserved Network | 23 | TPUL-192311A | 27G × 1/2″ |
As indicated in the dermal filler package insert.
Needles provided with the filler.
sHA, soluble hyaluronic acid.
Figure 1.Characterizations of the investigated gels. Size exclusion chromatography analysis of sHA released from the gels after extraction to assess (A) the mean Mw of the released sHA fragments, (B) the percentage of released sHA per syringe, and (C) the percentage of released low Mw sHA per syringe in the distribution ranges of [0–250 kDa], [0–100 kDa], and [0–30 kDa]. (D) 1H NMR analysis of the gels to assess the MoD of the enzymatically digested gels. sHA, soluble hyaluronic acid; MoD, degree of modification.
Figure 2.Scores of (A) Strength and (B) Stretch of the gel library.